Robert E. Gagnon
Net Worth

Last updated:

What is Robert E. Gagnon net worth?

The estimated net worth of Mr. Robert E. Gagnon is at least $3,206,205 as of 19 Dec 2024. He owns shares worth $273,403 as insider, has earned $327,922 from insider trading and has received compensation worth at least $2,604,880 in Verastem, Inc..

What is the salary of Robert E. Gagnon?

Mr. Robert E. Gagnon salary is $651,220 per year as Chief Bus. & Financial Officer in Verastem, Inc..

How old is Robert E. Gagnon?

Mr. Robert E. Gagnon is 51 years old, born in 1974.

What stocks does Robert E. Gagnon currently own?

As insider, Mr. Robert E. Gagnon owns shares in one company:

Company Title Shares Price per share Total value
Verastem, Inc. (VSTM) Chief Bus. & Financial Officer 34,477 $7.93 $273,403

What does Verastem, Inc. do?

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Robert E. Gagnon insider trading

Verastem, Inc.

Mr. Robert E. Gagnon has made 25 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 130 units of VSTM stock worth $568 on 19 Dec 2024.

The largest trade he's ever made was exercising 19,612 units of VSTM stock on 3 Jan 2022. As of 19 Dec 2024 he still owns at least 34,477 units of VSTM stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 130 $4.37 $568
Sale
Common Stock 285 $4.54 $1,294
Sale
Common Stock 131 $2.79 $365
Sale
Common Stock 287 $2.8 $804
Sale
Common Stock 131 $3.21 $421
Sale
Common Stock 283 $3.49 $988
Sale
Common Stock 130 $10.38 $1,349
Sale
Common Stock 283 $10.71 $3,031
Sale
Common Stock 9,204 $13.7 $126,095
Sale
Common Stock 9,204 $10.95 $100,784
Sale
Common Stock 130 $7.73 $1,005
Sale
Common Stock 284 $7.64 $2,170
Sale
Common Stock 130 $9.84 $1,279
Sale
Common Stock 278 $9.91 $2,755
Sale
Common Stock 130 $10.3 $1,339
Sale
Common Stock 283 $9.92 $2,807
Sale
Common Stock 1,664 $0.43 $716
Sale
Common Stock 1,429 $0.37 $529
Sale
Common Stock 12,408 $0.4 $4,963
Sale
Common Stock 1,348 $1.13 $1,523
Sale
Common Stock 1,351 $1.14 $1,540
Sale
Common Stock 16,627 $1.03 $17,126
Sale
Common Stock 1,409 $1.27 $1,789
Sale
Common Stock 19,612 $2.05 $40,205
Sale
Common Stock 5,497 $2.27 $12,478

Verastem key executives

Verastem, Inc. executives and other stock owners filed with the SEC:

  • Mr. Brian M. Stuglik BPHARM, R.Ph., RPh (66) Chief Executive Officer & Director
  • Mr. Daniel W. Paterson (64) Chief Operating Officer & Pres
  • Mr. Robert E. Gagnon (51) Chief Bus. & Financial Officer